SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ahlqvist Rastad Jane)
 

Sökning: WFRF:(Ahlqvist Rastad Jane) > Antiretroviral trea...

Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations

Sandström, Eric (författare)
Karolinska Institutet
Uhnoo, Ingrid (författare)
Uppsala universitet,Institutionen för medicinska vetenskaper,Infektion, Göran Friman
Ahlqvist-Rastad, Jane (författare)
visa fler...
Bratt, Göran (författare)
Karolinska Institutet
Berglund, Torsten (författare)
Karolinska Institutet
Gisslén, Magnus, 1962 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för infektionssjukdomar,Institute of Internal Medicine, Dept of Infectious Diseases
Lindbäck, Stefan (författare)
Morfeldt, Linda (författare)
Ståhle, Lars (författare)
Sönnerborg, Anders (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
2009-07-08
2003
Engelska.
Ingår i: Scand J Infect Dis. - : Informa UK Limited. ; 35:3, s. 155-67
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • The Swedish guidelines (SwG) for treatment of human immunodeficiency virus (HIV) infection have several important roles. A major task involves the promotion of a uniformly high standard of care in all HIV treatment clinics in Sweden and the identification of strengths, weaknesses and relevance of recent research findings. CD4+ T-cell counts < 200 cells/microl are clear indications for the initiation of treatment, whereas high viral loads serve as an indication for increased vigilance rather than a criterion for therapy. It is recommended that the first regimen consists of 2 nucleoside reverse transcriptase inhibitors in combination with 1 protease inhibitor or 1 non-nucleoside reverse transcriptase inhibitor. The definition of treatment failure is rigorous. Treatment change should be considered if the viral load has not fallen by at least 1.5 log in 4 weeks or is undetectable within 3-4 months. Resistance testing is endorsed at primary infection, in the event of treatment failure and in pregnant women. Interaction with experts in HIV resistance testing is emphasized. Therapeutic drug monitoring is advocated. Patients with treatment failure should be handled individually and the decision on therapeutic strategy should be based on treatment history, resistance testing and other clinical facts. The SwG do not give recommendations for some important issues such as prolonged drug holidays and preferences in initial treatment regimens. More scientific data are likely to be available soon and the SwG will be refined accordingly. The present guidelines are translated from Swedish; they are published on the Medical Products Agency (MPA) and Swedish Reference Group for Antiviral Therapy (RAV) websites (www.mpa.se and www.rav.nu.se), including 7 separate papers based on a thorough literature search. A complete reference list is available on request from the MPA.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

Anti-HIV Agents/*administration & dosage
Antiretroviral Therapy
Highly Active/*standards
Female
HIV Infections/diagnosis/*drug therapy
*Health Planning Guidelines
Humans
Male
Practice Guidelines as Topic
Prognosis
Sensitivity and Specificity
Survival Analysis
Sweden
Treatment Outcome
MEDICINE

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy